PCVX

Vaxcyte, Inc.

• Reuters·6d ago

  Vaxcyte SVP Finance Elvia Cowan disposes of USD 180,000 common shares

• Reuters·04/07 20:06

  Vaxcyte to present at Needham Virtual Healthcare Conference fireside chat

• Simply Wall St·04/04 18:14

  Vaxcyte (PCVX) Valuation Check As VAX-31 Phase 3 OPUS Trials Reach Full Enrollment

• Reuters·04/03 20:06

  Vaxcyte COO Jim Wassil disposes of common shares worth $0.1 million

• Simply Wall St·03/30 16:05

  Should Vaxcyte’s (PCVX) Fully Enrolled VAX-31 Phase 3 Trials Prompt a Portfolio Reassessment?

• NASDAQ·03/25 19:28

  Notable Wednesday Option Activity: PCVX, MRVL, CORT

• Reuters·03/25 11:30

  Vera Therapeutics appoints Jane Wright-Mitchell chief legal officer

• TipRanks·03/24 15:15

  Mizuho Securities Sticks to Its Buy Rating for Vaxcyte (PCVX)

• TipRanks·03/23 13:06

  Vaxcyte completes enrollment in Vaxcyte VAX-31 OPUS-1 trial

• Benzinga·03/23 12:35

  Vaxcyte Hits Enrollment Cap For Phase 3 Trials For VAX-31, A Pneumococcal Conjugate Vaccine Candidate

• Reuters·03/23 12:31

  Vaxcyte completes enrollment in OPUS-1 and OPUS-2 Phase 3 trials of VAX-31 in about 5,300 adults

• Reuters·03/23 12:30

  VAXCYTE INC - OPUS-3 PHASE 3 RESULTS EXPECTED IN FIRST HALF OF 2027

• Reuters·03/23 12:30

  VAXCYTE COMPLETES ENROLLMENT OF OPUS-1 AND OPUS-2 PHASE 3 TRIALS EVALUATING VAX-31 FOR THE PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE AND PNEUMONIA IN ADULTS

• Simply Wall St·03/22 02:12

  Will VAX-31’s Phase 3 OPUS Progress and Broader Serotype Coverage Change Vaxcyte’s (PCVX) Narrative

• Simply Wall St·03/20 23:12

  Assessing Vaxcyte (PCVX) Valuation After Strong VAX 31 Phase 1/2 Results In The Lancet